Back to results
US 10,946,005 B2Granted
Methods for shrinking pituitary tumors
AssigneeCorcept Therapeutics, Inc.
InventorAndreas Moraitis
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCorcept Therapeutics, Inc.
InventorAndreas Moraitis
Estimating the term…
Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient. Relacorilant may be administered in conjunction with other pituitary tumor targeting treatments, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments.
A method of reducing the size of a visible pituitary tumor in a patient, the method comprising selecting a patient suffering from a visible pituitary macroadenoma tumor who has not been treated with radiation, said pituitary tumor occupying a location within said patient, said selecting comprising imaging the pituitary tumor effective to determine that the pituitary tumor is a visible macroadenoma and to determine a first size of the pituitary tumor, and then, for three months, administering to the selected patient an effective amount of relacorilant, where relacorilant is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone), which has the following structure:
Dependencies are inferred from the claim text.